SCHEMBL1407899

SCHEMBL1407899

CC(C)(C)c1cc(N)n(-c2cccc(CN3CCOCC3)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NCF1 P14598 1/20 0.49
▸ NOS1 P29475 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPK14 Q16539 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ TNF P01375 1/20 0.41
▸ DDR2 Q16832 1/20 0.41
▸ PIK3CD O00329 1/20 0.41
▸ PIK3R2 O00459 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PIK3CB P42338 1/20 0.41
▸ PIK3CG P48736 1/20 0.41
▸ PIK3R5 Q8WYR1 1/20 0.41
▸ PIK3R3 Q92569 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30704930 1.00 NCF1 (0.49) NCF1NOS1MEN1KMT2AALDH1A1
SCHEMBL367853 0.89 TNF (0.44) MEN1KMT2AALDH1A1MAPK14TNF
SCHEMBL10070685 0.87 NCF1 (0.47) NCF1NOS1MEN1KMT2AALDH1A1
SCHEMBL1408300 0.87 MC4R (0.43) NCF1KMT2AALDH1A1MAPK14KDM4E
SCHEMBL1408447 0.87 HRH3 (0.46) NCF1NOS1MAPK14TNFABL1
SCHEMBL15007067 0.84 KMT2A (0.42) KMT2AALDH1A1MAPK14PIK3CDPIK3R2
SCHEMBL5047313 0.84 MEN1 (0.52) NCF1NOS1MEN1KMT2AMAPK14
SCHEMBL15007241 0.82 DHFR (0.45) MEN1KMT2AALDH1A1MAPK14KDM4E
SCHEMBL3188521 0.82 MAPK14 (0.62) MEN1KMT2AMAPK14HTTTNF
SCHEMBL15011461 0.81 TNF (0.52) ALDH1A1MAPK14KDM4EHTTTNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 — — US claimed
WO-2023237759-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR ANAGENESIS BIOTECHNOLOGIES (FR) 2023-12-14 — — WO disclosed
WO-2023237759-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR ANAGENESIS BIOTECHNOLOGIES (FR) 2023-12-14 — — WO disclosed
EP-4289427-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. Anagenesis Biotechnologies (FR) 2023-12-13 — — EP disclosed
EP-2788345-B1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARM SPA (IT) 2020-06-10 — — EP disclosed
US-9458154-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-04 — — US disclosed
US-9458154-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-04 — — US disclosed
US-20150057273-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-02-26 — — US disclosed
US-20150057273-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-02-26 — — US disclosed
US-20120184561-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2012-07-19 — — US disclosed
US-20090012079-A1 Triazolopyridine Compounds LEWTHWAITE RUSSELL ANDREW 2009-01-08 — — US disclosed
US-20090012079-A1 Triazolopyridine Compounds LEWTHWAITE RUSSELL ANDREW 2009-01-08 — — US disclosed
US-20090012079-A1 Triazolopyridine Compounds LEWTHWAITE RUSSELL ANDREW 2009-01-08 — — US disclosed
US-20080319005-A1 Phenylacetamides Suitable as Protein Kinase Inhibitors NOVARTIS AG (CH) 2008-12-25 — — US disclosed
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors NOVARTIS AG (CH) 2008-11-20 — — US disclosed
EP-1984363-A1 TRIAZOLOPYRIDINE COMPOUNDS Pfizer Limited (GB) 2008-10-29 — — EP disclosed
EP-1874770-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS Novartis Pharma AG (CH) 2008-01-09 — — EP disclosed
WO-2007091152-A1 TRIAZOLOPYRIDINE COMPOUNDS PFIZER LIMITED (GB) 2007-08-16 — — WO disclosed
WO-2007091152-A1 TRIAZOLOPYRIDINE COMPOUNDS PFIZER LIMITED (GB) 2007-08-16 — — WO disclosed
WO-2006108640-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012079-A1 Triazolopyridine Compounds MAPKAPK5, MAPK1, MAPK4 NCF1 804/4885NOS1 397/4885MEN1 4823/4885
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 NCF1 1264/4885NOS1 2637/4885MEN1 1929/4885
US-20120184561-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS MAP3K10, MAP3K20, MAP3K9 NCF1 2064/4885NOS1 2314/4885MEN1 3222/4885
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors MAP3K20, MAP3K1, MAP3K19 NCF1 1170/4885NOS1 2493/4885MEN1 2018/4885
US-20080319005-A1 Phenylacetamides Suitable as Protein Kinase Inhibitors MAP3K20, MAP3K10, MAP3K9 NCF1 2213/4885NOS1 2147/4885MEN1 3250/4885
US-20150057273-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAPK4 NCF1 1007/4885NOS1 597/4885MEN1 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback